Nama's AI scorecard currently rates NeoGenomics Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NEO's P/E ratio?

NeoGenomics trades at a trailing price-to-earnings ratio of 88.6.

When does NEO report earnings?

NeoGenomics's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.06.

What is the NEO price target?

The median analyst price target from 10 analysts is $22.00, with a range of $19.00 – $35.00.

Is NEO Shariah compliant?

Nama's AAOIFI-style screen reads NeoGenomics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

NeoGenomics (NEO)

Healthcare · Diagnostics Research · NASDAQ

NeoGenomics (NEO) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $2.18B, a trailing price-to-earnings ratio of 88.6 and a free-cash-flow yield of -1.0%. Over the most recent reported fiscal year, revenue grew 10.1%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +53.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-62.0%

How far the last close sits under the highest price of the past five years.

Market cap	$2.18B
Trailing P/E	88.6
Price / book	2.7
Price / sales	2.8
FCF yield	-1.0%
Dividend yield	—
Gross margin	44.8%
Operating margin	-6.2%
Net margin	-4.1%
Revenue growth (YoY)	+10.1%
Revenue growth (3-yr annual)	+12.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

NEO earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $0.06). Beat the EPS estimate in 3 of 3 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.07	$0.06	+16.7%	$209.25M
Q2 2026	Jul 28, 2026	$0.05	$0.03	+66.7%	$201.66M
Q1 2026	Apr 28, 2026	$0.01	—	—	$186.67M
Q4 2025	Feb 17, 2026	$0.06	$0.04	+50.0%	$190.17M

NEO analyst price target

Median target $22.00 from 10 analysts, ranging $19.00 – $35.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live NEO data on Nama Insights →

Recent Congressional trades

NeoGenomics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 10, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 6, 2025

NEO FAQ

Is NEO a buy?: Nama's AI scorecard currently rates NeoGenomics Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NEO's P/E ratio?: NeoGenomics trades at a trailing price-to-earnings ratio of 88.6.
When does NEO report earnings?: NeoGenomics's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.06.
What is the NEO price target?: The median analyst price target from 10 analysts is $22.00, with a range of $19.00 – $35.00.
Is NEO Shariah compliant?: Nama's AAOIFI-style screen reads NeoGenomics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.